They provided the revenue breakdown on page 12 of the MD&A which reads like this:
iaHealth - $53K, mHealth $43K for Q2
iaHealth $76K, mHealth $121K YTD
So iaHealth did grow QoQ from $23K to $53K but that's far too little too late imo. That mHealth division just looks pathetic. Not only did they spend their precious capital funding on it, now it's a major cash drain and revenues are badly tanking. This could be the goof of the year for the TSX biotech sector.
iaHealth on a standalone perspective doesn't look too bad - $155K loss on $53K revenue. That means had they solely focused on that instead of working on the purchase, they probably had enough cash to see the division breakeven around $200K in revenue/qtr by year end, then see the light at the end of the tunnel with respect to it being able to grow to pay their interest and corporate admin expenses in 2014.